Mollenhauer B - Search Results

1

CSF and blood biomarkers for Parkinson's disease.

Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P. Parnetti L, et al. Among authors: mollenhauer b. Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10. Lancet Neurol. 2019. PMID: 30981640 Review.

2

How to improve the clinical diagnosis of Creutzfeldt-Jakob disease.

Poser S, Mollenhauer B, Kraubeta A, Zerr I, Steinhoff BJ, Schroeter A, Finkenstaedt M, Schulz-Schaeffer WJ, Kretzschmar HA, Felgenhauer K. Poser S, et al. Among authors: mollenhauer b. Brain. 1999 Dec;122 ( Pt 12):2345-51. doi: 10.1093/brain/122.12.2345. Brain. 1999. PMID: 10581227

3

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease.

Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S. Otto M, et al. Among authors: mollenhauer b. Neurology. 2002 Jan 22;58(2):192-7. doi: 10.1212/wnl.58.2.192. Neurology. 2002. PMID: 11805244

4

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.

Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J. Bibl M, et al. Among authors: mollenhauer b. Brain. 2006 May;129(Pt 5):1177-87. doi: 10.1093/brain/awl063. Epub 2006 Apr 6. Brain. 2006. PMID: 16600985 Free PMC article.

5

Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.

Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG. Mollenhauer B, et al. Exp Neurol. 2008 Oct;213(2):315-25. doi: 10.1016/j.expneurol.2008.06.004. Epub 2008 Jun 14. Exp Neurol. 2008. PMID: 18625222

6

Neurochemical biomarkers in the differential diagnosis of movement disorders.

Mollenhauer B, Trenkwalder C. Mollenhauer B, et al. Mov Disord. 2009 Jul 30;24(10):1411-26. doi: 10.1002/mds.22510. Mov Disord. 2009. PMID: 19412961 Review.

7

Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.

Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Mollenhauer B, et al. Biomark Med. 2010 Oct;4(5):683-99. doi: 10.2217/bmm.10.90. Biomark Med. 2010. PMID: 20945981 Review.

8

CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.

Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, Wiltfang J, Bibl M. Mollenhauer B, et al. J Alzheimers Dis. 2011;24(2):383-91. doi: 10.3233/JAD-2011-101551. J Alzheimers Dis. 2011. PMID: 21297274

9

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. Mollenhauer B, et al. Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Lancet Neurol. 2011. PMID: 21317042

10

The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases.

Sixel-Döring F, Liepe K, Mollenhauer B, Trautmann E, Trenkwalder C. Sixel-Döring F, et al. Among authors: mollenhauer b. J Neurol. 2011 Dec;258(12):2147-54. doi: 10.1007/s00415-011-6076-z. Epub 2011 May 6. J Neurol. 2011. PMID: 21547379

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

347 results

Search Page